Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-09-09
1998-06-02
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
A61K 3143
Patent
active
057600260
ABSTRACT:
Lysostaphin is used to eliminate and cure staphylococcal infections including the cure of mastitis by intramammary infusion. Administration of from 2 mg to 400 mg of lysostaphin to an infected bovine mammary gland eliminates staphylococci, and the reoccurrence common with antibiotic therapy is not observed. Teat-dips containing lysostaphin, mutanolysin and lysozyme can be used as a prophylactic. Synergistic enhancement of the killing effect of lysostaphin is observed when a mild surfactant or penicillin or both is included in the formulation.
REFERENCES:
patent: 3278378 (1966-10-01), Schindler et al.
patent: 3398056 (1968-08-01), Zygmunt et al.
patent: 3427377 (1969-02-01), Baver et al.
patent: 3594284 (1971-07-01), Zygmunt et al.
patent: 3636194 (1972-01-01), Parizeau
patent: 4011312 (1977-03-01), Rueter et al.
patent: 4931390 (1990-06-01), Rescei
N. Craven et al., "pH-dependent Penicillin Tolerance May Protect Intraleukocytic Staphylococcus aureus from killing by Cloxacillin," 21 Antimicrobial Agents & Chemotherapy 618 (1982).
Khan et al., J. Dairy Sci 52, 895.
The Vet Clinics of North America, vol. 6, No. 2 (1984) Jarret, W.B. Saunders Co. pp. 338-343.
The Merck Manual, Fifth Edition, Merck & Co. (1979) p. 841.
E.F. Harrison et al., "Comparative In Vitro Activities of Antibiotics on Clinical Isolates of Styphylococcus aureus," 13 Applied Microbiol 212 (1965).
W.A. Zygmunt et al., "Susceptibility of Coagulase-negative Staphylococci to Lysostaphin and Other Antibiotics," 16 Applied Microbiol. 1168 (1968).
G. Pulverer et al., "Susceptibility of Staphylococcus epidermidis to Lysostaphin and Major Antimicrobial Agents," 19 Chemotherapy 109 (1973).
W. Schaffner et al., "Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. I. In Vitro Studies," 39 Yale J. Biol. & Med. 215 (1967).
B.F. King et al., "Facile Penetration of the Staphylococcus aureus Capsule by Lysostaphin," 29 Infection & Immunity 892 (1980).
K.E. Quickel, Jr. et al., "Efficacy and Safety of Topical Lysostaphin Treatment of Persistent Nasal Carriage of Staphylococcus aureus," 22 Applied Microbiol. 446 (1971).
E.F. Harrison et al., "Antigenic Response to Topically Applied Proteins," 11 Infection & Immunity 309 (1975).
F.R. Stark et al., "Systemic Lysostaphin in Man--Apparent Anti-Microbial Activity in Neutropenic Patient," 291 Medical Intelligence 239 (1974).
Dixon et al., "Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. III. Combined Lysostaphin-Methicillin Therapy of Established Staphylococcal Abscesses in Mice," 41 Yale J. Biol. & Med. 62, (1968).
R.R. Martin et al., "The selective activity of lysostaphin in vivo," 70 J. Laboratory & Clinical Medicine 1 (1967).
R.R. Martin et al., "The reacqui-sition of staphylococci by treated carriers: A demonstration of bacterial interference," 71 J. Laboratory & Clinical Med. 791 (1968).
W.A. Zygmunt et al., "Lysostaphin: Model for a Specific Enzymatic Approach to Infectious Disease," 16 Prog. Drug Research 309 (1972).
M.L. Garcia et al., "Characterization of Staphylococci Isolated From Mastitic Cows in Spain," 39 Applied Environ. Microbiol. 548 (1980).
L. Gutierrez et al., "Sensitivity of Lysostaphin as a Criterion for the Identification of Staphylococci from Animal Origin," 50 J. Applied Bacteriol 541 (1981).
B.A. Gunn et al., "Comparison of Methods for Identifying Staphylococcus and Micrococcus spp.," 14 J. Clinical Microbiol. 195 (1981).
P.J. Severance et al., "Rapid Identification of Staphylococcus aureus by Using Lysostaphin Sensitivity," 11 J. Clinical 724 (1980).
N. Craven et al., "pH-dependent Pencillin Tolerance May Protect Intraleukocytic Staphylococcus aureus from Killing by Cloxacillin," 21 Antimicrobial Agents & Chemotherapy 618 (1982).
P.J. van den Broek et al., "Adherence of Lysostaphin to and Penetration Into Human Monocytes," 21 Scand J. Immunol 189 (1985).
N. Craven et al., "The effects of cloxacillin on staphylococci phagocytosed by bovine neutrophils," 29 Research in Veterinary Science 57 (1980).
N. Craven et al., "Antibiotic activity against intraleukocytic Staphylococcus aureus in vitro and in experimental mastitis in mice," 44 Amer. J. Vet. Res. 709 (1983).
N. Craven et al., "Enhanced Killing of Penicillin-Treated S. Aureus by Host Defences: Effects of Amoxycillin, Cloxacillin and Nafcillin in vitro and in Experimental Mastitis," 5 Comp. Immum. Microbiol. Infect. Dis. 447 (1982).
M.J. Paape et al., "Measurement of Phagocytosis of .sup.32 P-Labeled Staphylococcus aureus by Bovine Leukocytes: Lysostaphin Digestion and Inhibitory Effect of Cream," 36 Amer. J. Vet. Res. 1737 (1975).
R.K. Root et al., "Interactions Between Antibiotics and Human Neutrophils in the Killing of Staphylococci,"67 J. Clinical Invest. 247 (1981).
G. Ziv. et al., "Influence of antibiotics and intramammary antibiotic products on phagocytosis of Staphylococcus aureus by bovine leukocytes," 44 Amer. J. Vet. Res. 385 (2983).
N. Craven et al., "Phagocytosis of Staphylococcus aureus by Bovine Mammary Gland Macrophages and intracellular protection from antibiotic action in vitro and in vivo," 51 J. Dairy Research 513 (1984).
J.S. McDonald "Streptococcal and Staphylococcal Mastitis," 6 Vet. Clinics No. Amer. Large Animal Practice 269 (1984).
A. Franklin et al., "Antimicrobial Drug Susceptibility of Staphylococcus aureus Strains Isolated from Bovine Milk," 34 Nord. Vet.-Med. 460 (1983).
R.J. Yancey, Jr. et al., "Efficacy of lincosaminide antibiotics in the treatment of experimental staphylococcal mastitis in lactating mice," 15 J. Antimicrobial Chemotherapy 219 (1985).
N. Craven et al., "Penicillin (cloxacillin)-tolerant Staphylococcus aureus from bovine mastitis: identification and lack of correlation between tolerance in vitro and response to therapy in vivo," 34 Research Vet. Sci. 266 (1983).
G. Cisani et al., "High-Level Potentiation of Lysostaphin Anti-Staphylococcal Activity by Lysozyme," 21 Antimicrobial Agents and Chemotherapy 531 (1982).
Hirt et al., J. Reticuloendothelial Soc. 13, 27-46 (1973).
Rayburn et al., Clinical Research, p. 607A.
Mansour et al., Amer. Soc. Microbiol. Annual Meeting Abstract D69 (1983).
Frederick et al. Ann. Rev. Resp. Dis 133, A68 (1986).
G.L. Mandell, J. Clinical Investigation 52, 1673-1679 (1973).
J.N. Sheagren, New England J. Medicine 310, 1437-1442 (1984).
Severance et al., J. Clinical Microbiol. 12, 709-710 (1984).
Martin et al., Clinical Research, 341 (19 ).
Gunn et al., 214 (19 ).
M.G. Koenig, J. Infect. Dis 119, 101-102 (1969).
Schaffner et al., Clinical Research, 343 (19 ).
Jones et al., Henry Ford Hosp. Med. J. 16, 234-238 (1968).
Quinn et al., Antimicrobial Agents and Chemotherapy 1966, 382-388 (1967).
Khan et al., J. Dairy Sci 52, 895.
Kato et al., Bikin J. 29, 39-44 (1986).
D.E. Rogers, Posteopy Mikrobiologii 5, 279-296 (1966).
Plhackova et al., Folia Microbiol. 16, 517 (1971).
G. Pulverer, Dtsch med. Wschr 92, 2236-2238 (1967).
Dixon, R. E., Goodman, J.S., and Koenig, M.G., Lysostaphin: An Enzymatic Approach to Staphylococcal Disease. III. Combined Lysostaphin-Methicillin Therapy of Established Staphylococcal Abscesses In Mice. Yale J. Biol. Med, 41:62-68, 1968.
The Merck Veterinary Manual, Fifth Ed. Merck & Co (1979) p. 841.
Formulation of Veterinary Dosage Forms, J. Blodinger (ed), Marcel Dekker, Inc, (New York Msal Basel ) 1983, pp. 155-156.
The Merck Index, 10th ed, (Merck & Co, Inc, 1983) #5457, p. 5459.
Am. J. Vet. Res., vol. 44, No. 4, pp. 709-712 Apr. 1983.
The Merck Veterinary Manual, Fifth Edition, Merck & Co. (1979) pp. 840 & 842-849.
The Vet. Clinics of North America, vol. 6/No. 2 Jul. 1984 Jarrett, W.B. Saunders Co. pp. 338-343.
Blackburn Peter
Polak June
Ambi Inc.
Weddington Kevin E.
LandOfFree
Method for treating mastitis and other staphylococcal infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating mastitis and other staphylococcal infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating mastitis and other staphylococcal infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459931